Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of ...

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...

“Our higher target reflects confidence in Dupilumab’s commercial COPD opportunity, adding to our already positive outlook for Regeneron on an ophthalmology franchise renewed by 8mg ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than 300,000 adults and adolescents aged 12 years and ...

Sanofi and Regeneron chimed in with an update on their versatile biologic Dupixent (dupilumab), which is closing in on a potential COPD approval. The NOTUS trial—the second of two phase 3 ...

Data from prior Sanofi/Regeneron studies further supports ... on high-dose ICS plus placebo. The VESTIGE trial, meanwhile, demonstrated that dupilumab led to reductions in mucus plugging and ...

The safety profile of dupilumab was consistent with that observed in previous clinical trials. Adverse events ... President and Chief Scientific Officer at Regeneron, and a principal inventor ...

First and only investigational Phase 3 trial to show positive results in these young children; results follow recent approval of Dupixent in people with eosinophilic esophagitis aged 12 years and ...

Dupilumab is a human monoclonal antibody ... was developed by the trial sponsors (Sanofi and Regeneron Pharmaceuticals) and three of the authors. Data were collected by the investigators and ...